Načítá se...
Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial
BACKGROUND: The experiences of biomarker-ineligible cognitively normal persons can inform trial conduct and the translation of preclinical Alzheimer’s disease (AD) into clinical practice. METHODS: We interviewed 33 persons whose “not elevated” brain amyloid imaging biomarker result made them ineligi...
Uloženo v:
| Vydáno v: | Alzheimers Res Ther |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6303934/ https://ncbi.nlm.nih.gov/pubmed/30579361 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-018-0452-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|